Catalyst

Slingshot members are tracking this event:

Bayer (BAYRY) Releases Phase 3b PIONEER AF-PCI Results Evaluating Xarelto in Patients with Irregular Heartbeat After Percutaneous Coronary Intervention at the American Heart Association Scientific Sessions 2016

Source Link:
http://www.press.bayer.com/baynews/baynews.nsf/id/Bayers-Xarelto-Significantly-Reduced-Bleeding-Compared-VKA-AF-Patients-Receiving-Antiplatelet?OpenDocument&sessionID=1479146614

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
BAYRY
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Nov 14, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3b, Pioneer Af-pci, Xarelto, Irregular Heartbeat, Percutaneous Coronary Intervention, American Heart Association, Scientific Sessions 2016
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.